| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J |
NCT01458379: Brain Myelination Effects of Paliperidone Palmitate Versus Oral Risperidone in First Episode Schizophrenia |
|
|
| Not yet recruiting | 4 | 50 | US | Paliperidone Palmitate, Risperidone | University of California, Los Angeles, Ortho-McNeil Janssen Scientific Affairs, LLC | Schizophrenia | 10/14 | 12/15 | | |
2022-001582-12: Open, multicenter, randomized clinical trial to evaluate the efficacy and safety of aripiprazole vs paliperidone / risperidone using multi-omics data in patients with a first psychotic episode. Ensayo clínico abierto, multicéntrico, aleatorizado para evaluar la eficacia y seguridad de aripiprazol vs paliperidona / risperidona mediante datos multi-ómicos en pacientes con un primer episodio psicótico. |
|
|
| Ongoing | 4 | 244 | Europe | Injection, Abilify Maintena, Xeplion | Consorcio Centro de Investigacion Biomedica en Red (CIBER), Instituto de Salud Carlos III | First episode SZ-spectrum individuals Pacientes con un primer episodio psicótico, First episode SZ-spectrum individuals Pacientes con un primer episodio psicótico, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
CASPAR, NCT04940039: A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings |
|
|
| Completed | 4 | 93 | RoW | Risperidone 3 mg, Paliperidone Palmitate 50 mg eq., R092670, Paliperidone Palmitate 75 mg eq., Paliperidone Palmitate 100 mg eq., Paliperidone Palmitate 150 mg eq., Paliperidone Palmitate 175 mg eq., Paliperidone Palmitate 263 mg eq., Paliperidone Palmitate 350 mg eq., Paliperidone Palmitate 525 mg eq. | Janssen-Cilag International NV | Schizophrenia | 04/24 | 04/24 | | |
NCT02772393 / 2015-004835-10: A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation |
|
|
| Recruiting | 3 | 300 | Europe, RoW | Paliperidone palmitate 3 month formulation (PP3M) | Janssen-Cilag Ltd., Janssen-Cilag International NV | Schizophrenia | 12/17 | 03/18 | | |
| Recruiting | 2/3 | 240 | RoW | Aripiprazole, Paliperidone, Treatment as Usual | The University of Hong Kong, Queen Mary Hospital, Hong Kong, North District Hospital | Stimulant Use With Stimulant-Induced Psychotic Disorder (Diagnosis), Schizophrenia and Related Disorders, Stimulant Dependence, Stimulant Abuse, Pharmacotherapy | 05/24 | 05/25 | | |
NCT04922593: Relative Bioavailability of LY03010 Compared to Listed Drug |
|
|
| Completed | 1 | 281 | US | LY03010; paliperidone palmitate, INVEGA SUSTENNA | Luye Pharma Group Ltd. | Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum, Mental Disorders, Antipsychotic Agents, Tranquilizing Agents, Central Nervous System Depressants, Physiological Effects of Drugs, Psychotropic Drugs, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action | 03/22 | 04/22 | | |
NCT05321602: Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder |
|
|
| Completed | 1 | 89 | US | LY03010 156 mg treatment group, deltoid, paliperidone palmitate, LY03010 156 mg treatment group, gluteal, LY03010 351 mg treatment group, deltoid, LY03010 351 mg treatment group, gluteal | Luye Pharma Group Ltd. | Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, Mental Disorders, Antipsychotic Agents, Tranquilizing Agents, Central Nervous System Depression, Physiological Effects of Drugs, Psychotropic Drugs, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action | 09/22 | 10/22 | | |
NCT01359293: Effects of Paliperidone Palmitate Versus Oral Antipsychotics on Clinical Outcomes and MRI Measures |
|
|
| Recruiting | N/A | 120 | US | paliperidone palmitate, Sustenna, oral antipsychotics | University of Iowa, Wishard Health Services | Schizophrenia, Schizophreniform | 04/14 | 12/14 | | |
ACTRN12618002059246: Acceptability of WAKA - a new online support tool for people living with schizophrenia on paliperidone injection |
|
|
| Not yet recruiting | N/A | 60 | | | Dr Lyndy Matthews, Janssen Pharmaceutical Companies (Johnson & Johnson New Zealand) | Schizophrenia | | | | |